ArticleBMC musculoskeletal disorders2025
PRP and hypertonic glucose injections improve outcomes in patients with early- to middle-stage knee osteoarthritis: a multicenter retrospective study.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The efficacy and safety of platelet rich plasma and hyaluronic acid in the treatment of knee osteoarthritis: a meta-analysis.Frontiers in surgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlatelet-rich plasma (PRP) injection therapy and hyperosmotic glucose hyperplasia therapy are commonly used methods for treating knee osteoarthritis (KOA). This study evaluates the differences in efficacy and cost-effectiveness between the two therapies.
methodsThis study retrospectively analyzed 257 patients with knee osteoarthritis from October 2021 to November 2023, and divided them into PRP injection group and hypertonic glucose injection group according to their different treatment methods. All patients underwent a 4-week treatment. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Visual Analog Scale (VAS) scores were compared at baseline and 2, 4, 8, 16, and 32 weeks after treatment. Additionally, differences in the 36-Item Short Form Health Survey (SF-36) scores and total expenses during the treatment period were assessed between the two groups at the same time points.
resultsAt 2 and 4 weeks post-treatment, the VAS and WOMAC scores of the hypertonic glucose injection group were lower than those of the PRP injection group. Conversely, at 16 and 32 weeks post-treatment, the PRP injection group demonstrated lower VAS and WOMAC scores than the hypertonic glucose injection group. Similarly, SF-36 scores at 2 and 4 weeks post-treatment were higher in the hypertonic glucose injection group, whereas at 16 and 32 weeks, the PRP injection group achieved higher SF-36 scores. Regarding cost-effectiveness, the total cost for the PRP injection group was 362.4, while for the hypertonic glucose injection group, it was 87.4, making the latter more economical.
conclusionBoth PRP and hypertonic glucose injections significantly alleviate knee pain and improve joint function, enhancing patients’ quality of life. However, hypertonic glucose injections demonstrate superior short-term efficacy and lower costs. PRP injections, in contrast, provide better medium- to long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.